Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Why was the G551D mutation selected for the VX-770 Phase 2 clinical trial?

April 26, 2017clinical trial g551d mutation phase Selected vx-770

0

Posted

Why was the G551D mutation selected for the VX-770 Phase 2 clinical trial?

1 Answer

0

Posted

The G551D mutation was selected because the protein resulting from this mutation is located at the cell’s surface, waiting to function as a chloride channel, but does not function properly. VX-770 acts to increase the function of the CFTR chloride channel that is already at the cell surface.